Financial Shenanigans

The Forensic Verdict

Forensic Risk Score: 27 / 100 — Watch. Constellation runs an unusually clean book for an aggressive serial acquirer, but the headline cash-flow story leans on three structural levers that an investor should price in: a $1.2 billion put-option liability to the Joday Group whose mark-to-market drives most of the GAAP earnings noise; an intangibles base that is now 52% of total assets and a $1.4 billion annual amortization charge that mechanically pushes the CFO/NI ratio to 5x; and a custom non-IFRS metric (FCFA2S) that is the lens management asks investors to use rather than reported CFO. No restatement, no auditor resignation, no SEC or short-seller action, and the FY2025 retrospective adjustment was a $34 million boost to Q1 2025 net income (immaterial in scale). The single observation that would change the grade is a step-down in the IRGA put exercise window — if the Joday Group actually exercises, the $1.2B liability becomes a cash obligation rather than a recurring P&L revaluation.

Shenanigans scorecard — all 13 categories

Breeding Ground

Breeding-ground risk is low to moderate. The compensation architecture is one of the most owner-aligned among large-cap technology companies; the governance vulnerability is concentrated in the long-tenure auditor and the put-option relationship with a controlling minority shareholder of the Topicus subsidiary.

Incentive design and tone at the top

The named-executive incentive structure is materially different from peer practice:

• No options, no RSUs, no PSUs. Bonus is cash, but 75% of the after-tax amount must be used to buy CSU common shares (or Topicus shares for Topicus executives) on the open market and held in escrow for a minimum 4-year average.
• The bonus formula is Base × Company Performance Factor × Individual Factor, where the Company Performance Factor is driven by ROIC (net income for bonus purposes ÷ Average Invested Equity Capital) minus a 5% risk-free hurdle, plus net revenue growth. ROIC must exceed 5% or the manager earns zero bonus.
• "Net income for bonus purposes" excludes deferred taxes, unrealized FX, bargain purchase gains, contingent consideration expense, redeemable preferred securities expense, NCI deductions, and intangible amortization & impairments. The exclusions are mostly genuine non-cash or non-economic items, but they are also items management has discretion over (contingent consideration in particular).
• Founder Mark Leonard waived all salary and bonus in 2023, 2024 and 2025; new President Mark Miller has waived for 2026 onward. CEO transition occurred September 25, 2025.

The only meaningful structural risk is auditor tenure. KPMG has audited Constellation since 1995, predating the 2006 IPO. Canadian rules permit indefinite tenure with periodic partner rotation, but a three-decade engagement is well outside the EU-style 10-year ceiling and reduces the margin of safety on independence. Nothing in the public record suggests audit quality has suffered, but the tenure is worth surfacing for an investor who treats long auditor relationships as a yellow flag.

Earnings Quality

Reported earnings are noisy because of three non-cash lines that flow through pretax income — but the underlying revenue, cost, and accrual behavior is sound.

Revenue vs receivables: no daylight

FY2025 revenue grew 15.5%, receivables grew 15.7%. The gap is essentially zero, and DSO has been pinned between 60.2 and 63.5 days for four years after a one-time step-up in FY2022 (from 53 days), which corresponds to the May 2022 Altera acquisition from Allscripts (a hospital-software business with longer collection cycles than CSU's typical municipal-software target). No bill-and-hold, no extended quarter-end terms, no factoring program disclosed.

GAAP earnings bridge: where the noise comes from

Net income to common shareholders fell from $731M in FY2024 to $512M in FY2025, a 30% decline that headline-readers would flag as an earnings deterioration. The decline is essentially explained by two non-cash and one income-tax item.

The IRGA liability revaluation and the Asseco reclassification together explain a $517M swing in pretax income with zero cash impact. Both are mechanical consequences of accounting standards applied to real economic positions — the IRGA liability rises when Topicus's recurring revenue and equity holdings rise; Asseco was reclassified from fair-value to equity-method-at-cost when CSU's ownership crossed the significant-influence threshold in September 2025. Neither is manipulation. Both are evidence that GAAP NI is a poor read of CSU's economic earnings in any given period.

Reserves, capitalization, impairment — clean tests

The single test worth watching is contingent consideration expense, which moved from $8M in FY2024 to $35M in FY2025. The accrual is updated quarterly based on management's revenue forecasts for acquired companies, so it is mechanically discretion-heavy. The line itself is not material at $35M against $11.6B of revenue, but the discretion to update earnout accruals is a lever a less-honest acquirer could use to smooth post-deal earnings. At Constellation's current materiality it does not change the picture.

Cash Flow Quality

Operating cash flow is real cash but the conversion ratio is mechanical, not magical, and the "free cash flow" headline understates what the business actually consumes.

CFO vs Net Income — the 5x ratio is amortization, not alchemy

The reason CFO is 5.1× net income over the last three years is that amortization of acquired intangibles ($1.4B in FY2025) is the largest single add-back in the cash-flow reconciliation. In other words, CSU's "earnings" are charged with the amortization of the goodwill-like value of every acquired customer relationship, while the cash that those relationships throw off rolls into CFO each year. This is structurally consistent with the serial-acquirer model and is not a manipulation. It does, however, mean that any investor using "CFO / Net Income > 1" as a quality screen will mechanically score CSU as pristine when the underlying truth is more nuanced.

Free cash flow after acquisitions — the number that matters

The headline FCF over the five-year window totals $9.1B. After spending $7.3B on acquisitions, the residual is $1.7B — about $345M a year of genuinely uncommitted cash, which roughly matches the $85M annual dividend plus modest balance-sheet build. Acquisition spend in FY2025 fell to $1.34B (its lowest since 2021), which is the reason FCF after acquisitions stepped up sharply to $1.32B. This is not a red flag — it is just the correct denominator for thinking about Constellation's "real" cash generation under the buy-and-hold-forever model.

Working-capital contribution to CFO is approximately zero

Capex is structurally trivial

Capex is 5% of D&A because the business genuinely does not require capital expenditure — depreciation of physical assets is around $200M and amortization of acquired intangibles is the other $1.2B. The corollary is that any forensic analyst should not treat the headline FCF of $2.66B as a maintenance-FCF number; the maintenance number is whatever revenue can be retained with zero acquisition spend, which on Constellation's own disclosure tracks organic growth of around 4% (about 1-3% FX-adjusted in FY2025).

Metric Hygiene

Management asks investors to use a custom cash-flow metric (FCFA2S) and a custom organic-growth metric. Both are disclosed and reconciled, but neither is GAAP.

Non-IFRS metric reconciliation

The FCFA2S definition is unusually complex for a metric used as the primary cash benchmark. Of the $1,049M gap between FY2025 CFO ($2,732M) and FCFA2S ($1,683M), the breakdown is: IRGA revaluation $440M (correctly removed as non-cash), interest paid $209M, lease payments $131M, capex $68M, debt transaction costs $13M, NCI portion $243M, offset by interest/dividends received $56M. Every adjustment is defensible, but the metric is custom and the four-year history is not directly comparable to peer FCF.

The non-IFRS bonus metric ("net income for bonus purposes") is the more important hygiene watch-item. The excluded items include contingent consideration expense — a line that grew 354% YoY in FY2025 — and unrealized FX swings of $154M. Excluding both from the executive bonus base is reasonable but it also removes the items most under management's discretion.

What to Underwrite Next

Five things to track. None is thesis-breaking; each would move the forensic grade if it tipped the wrong way.

1. IRGA put exercise window (highest priority). The $1.23B IRGA liability currently sits on the balance sheet as a non-cash mark-to-market line. If any member of the Joday Group exercises the put on its 38.1M Topicus Coop Units, CSU is obligated to buy 33.33% within 30 days and the rest over the following two years. Watch quarterly disclosures for any exercise notice. Disconfirming signal: a multi-year period of zero put activity would reduce the volatility-of-GAAP-NI concern. Confirming signal: a partial exercise would crystallize a portion of the $1.23B into cash outflow.

2. KPMG audit relationship. Watch for partner rotation disclosure, change in audit fee mix (audit vs non-audit), or any qualified opinion / emphasis-of-matter paragraph. Disconfirming signal: routine audit committee report each year confirming partner rotation. Confirming signal: any change in auditor that surfaces before the 30+ year tenure is voluntarily ended.

3. Contingent consideration accrual ($215M balance). The 354% jump in FY2025 expense ($8M → $35M) is small in absolute terms but the accrual is judgment-heavy. Disconfirming signal: stable or declining expense as historical earnouts cycle through. Confirming signal: large reserve releases coinciding with earnings shortfalls.

4. Q1 2025 recast detail in 2026 interim filings. Management has disclosed it will recast Q1 2025 comparatives in 2026 to reflect a $34M NI uplift (driven by Asseco-related finance income reclassification). Disconfirming signal: clean recast tying to Note 5 of the H1 2025 interim FS. Confirming signal: any additional retrospective adjustments creeping in alongside the disclosed one.

5. Q4 2025 subsidiary covenant breach. $51M term loan reclassified to current liability after a $2M cash-position breach (administrative, not financial-performance). Disconfirming signal: written waiver received from lender in 2026 as guided. Confirming signal: further covenant issues in other subsidiary-level facilities — the without-recourse debt stack is now $2.64B across many separate facilities.

Bottom line

The forensic risk here is a footnote, not a valuation haircut. Investors should price three things into the model: (i) GAAP net income will continue to be a noisy proxy for economic earnings as long as the IRGA put liability and equity-method investments sit on the balance sheet — use FCFA2S and adjusted earnings, but verify the adjustments yourself; (ii) headline FCF needs to be reduced by ongoing acquisition spend of roughly $1.5B per year before being treated as distributable cash; (iii) the 30-year audit tenure is not a defect but it is the one structural item that should keep an analyst from rounding the forensic grade to "Clean." Position sizing and required margin of safety do not need to be adjusted for accounting risk; what they should be adjusted for is the volatility-of-reported-earnings risk that the IRGA mark-to-market and the Asseco-style reclassifications will keep producing.